key: cord-0012001-svhh57v4
authors: nan
title: 合并肢端缺血表现的危重型新型冠状病毒肺炎七例临床分析
date: 2020-04-03
journal: Zhonghua Xue Ye Xue Za Zhi
DOI: 10.3760/cma.j.issn.0253-2727.2020.0006
sha: a222ae8f247d0914ada14921292787d23a5531ab
doc_id: 12001
cord_uid: svhh57v4

OBJECTIVE: To investigate the clinical and coagulation characteristics in patients with critical Coronavirus disease 2019 (COVID-19) and acro-ischemia. METHODS: The retrospective study included 7 critical COVID-19 patients with acro-ischemia in an intensive care unit (ICU) in Wuhan, from Feb 4 to Feb 15, 2020. The clinical and laboratory data before and during the ICU stay were analyzed. RESULTS: The median age of 7 patients was 59 years and 4 of them were men. Three patients were associated with underlying comorbidities. Fever, cough, dyspnea and diarrhea were common clinical symptoms. All patients had acro-ischemia presentations including finger/toe cyanosis, skin bulla and dry gangrene. D-dimer, fibrinogen and fibrinogen degradation product (FDP) were significantly elevated in most patients. Prothrombin time was prolonged in 4 patients. D-dimer and FDP levels progressively elevated consistent with COVID-2019 exacerbation. Four patients were diagnosed with disseminated intravascular coagulation (DIC). Low molecular weight heparin (LMWH) was administrated in 6 patients, which reduced D-dimer and FDP rather than improved clinical symptoms. Five patients died finally and the median time from acro-ischemia to death was 12 days. CONCLUSION: Coagulation parameters should be monitored closely in critical COVID-2019 patients. The timing and protocol of anticoagulation therapy are still under investigation based on more clinical data.

量血管活性药物 (去甲肾上腺素＜0.3 μg·kg -1 ·min -1 ) ， 同期动脉血气分析示乳酸含量均不高 (＜2.0 mmol/L) ， 无躯干及膝关节等部位皮肤花斑等。 所有患者均接受人丙种球蛋白 (5～20 g/d×5 d) 及大剂量维生素 C (100 mg·kg -1 ·min -1 ) ， 其中 5 例患 者 于 发 病 初 期 接 受 糖 皮 质 激 素(甲 泼 尼 龙 40～ 80 mg/d， 3～5 d) 治疗。6 例患者接受了低分子肝素 抗凝治疗， 剂量为 100 IU/kg， 每日 2 次， 抗凝中位治 疗时间为 8 (3～14) d， 抗凝治疗中未出现消化道出 血、 颅内出血、 气道出血、 深部血肿等严重出血事 件。末次随访日期为 3 月 2 日， 5 例患者死亡， 起病 至死亡的中位时间为 26(25～36)d， 肢端缺血至死 亡的中位时间为 12 (7～16) d， 死亡原因均为重度低 氧血症及呼吸性酸中毒导致的循环衰竭。2 例存活 患者仍在 ICU 治疗， 肺部情况未见好转， 未脱离机 械通气。例 3 足底缺血有所改善， 但例 2 下肢缺血 进行性加重， 已出现肢端坏疽。 二、 实验室检查 1. 入院时： 所有患者均存在不同程度淋巴细胞 减 少［ (0.37～1.09)× 10 9 /L) ］， 2 例 患 者 WBC 升 高 ［ (11.05～13.08) ×10 9 /L］ ， 1 例患者轻度贫血。所有 患者 ALT、 血肌酐水平均在正常范围， 低白蛋白血 症 及 LDH 升 高 比 例 为 85.7％ ， 心 肌 肌 钙 蛋 白 I (cTnI) 升高比例为 42.9％。所有患者均存在超敏 C 反应蛋白(hsCRP)升高(47～133 mg/L， 正常参考 值＜1 mg/L) 。所有患者入院时 PLT 均在正常范围 ［ (136～350)×10 9 /L］， D-二 聚 体 水 平(纤 维 蛋 白 原等 量 单 位 ， FEU)1.25～21.00 μ g/ml (正 常 参 考 值＜0.50 μg/ml) ， 中位数为 7.13 μg/ml。83.3％ (5/6) 的患者出现纤维蛋白降解产物(FDP)升高(9.6～ 150.0 μg/ml， 正常参考值＜5 μg/ml) 。85.7％的患者

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study［J］

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia［J］

试行第七 版) ［Z］ . 2020 年 3 月, 国卫办公函 ［2020］ 184 号

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS ［J］

Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus［J］

Clinical Characteristics of Coronavirus Disease 2019 in China［J］

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Role of Infectious Diseases in the Antiphospholipid Syndrome(Including Its Catastrophic Variant) ［J］

Catastrophic antiphospholipid syndrome(CAPS)induced by influenza A virus subtype H1N1［J］

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study［pub-lished online ahead of print